Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients

Autor: Ossa-Echeverri Sergio, Barraza-Bengoechea Julio César, Iglesias-Posadilla David, Gero-Escapa María, Callejo-Torre Fernando, Megías-Lobón Gregoria, Delgado-López Pedro, Colazo-Burlato María, Lorenzo-Martín Andrés, Fernández-Regueras María, Galacho-Harriero Ana, De La Torre-Ferrera Noelia, García-Muñoz Juan Pablo, Ubeira Iglesias Marta, Hermida-Fernández Gerardo, Buzón-Martín Luis, Montero-Baladía Miguel, Astigarraga Itziar, López-Veloso María, Boado-Lama Jorge, Iglesias-Julián Enrique, Fernández-Ratero José Antonio, Fisac-Cuadrado Lourdes, San Llorente Sebastián Rodrigo, Navarro-San Francisco Carolina, Simón-Rodríguez Adolfo, Minguito de la Iglesia Javier

Publikováno v: Journal of Translational Autoimmunity
Addi. Archivo Digital para la Docencia y la Investigación
instname
Journal of Translational Autoimmunity, Vol 4, Iss, Pp 100086-(2021)

Introduction: A growing evidence suggests that immune dysregulation and thrombotic phenomena are key features in the pathophysiology of COVID-19. Apart from antivirals and respiratory support, anticoagulants, corticoids and immunomodulators are incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e3aa94f03e74b3aa4edc47567ca999
http://europepmc.org/articles/PMC7879932